Market Cap
US$458.1m
Last Updated
2021/01/18 23:52 UTC
Data Sources
Company Financials +
Executive Summary
Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research worldwide. More Details
Rewards
Risk Analysis
Currently unprofitable and not forecast to become profitable over the next 3 years
Snowflake Analysis
Excellent balance sheet and overvalued.
Similar Companies
Share Price & News
How has Fluidigm's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: FLDM is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: FLDM's weekly volatility has decreased from 19% to 11% over the past year.
Market Performance
7 Day Return
-2.3%
FLDM
-0.008%
US Life Sciences
-0.4%
US Market
1 Year Return
46.4%
FLDM
45.7%
US Life Sciences
19.5%
US Market
Return vs Industry: FLDM matched the US Life Sciences industry which returned 45.7% over the past year.
Return vs Market: FLDM exceeded the US Market which returned 19.6% over the past year.
Shareholder returns
| FLDM | Industry | Market | |
|---|---|---|---|
| 7 Day | -2.3% | -0.008% | -0.4% |
| 30 Day | -9.9% | 6.8% | 2.3% |
| 90 Day | -11.0% | 15.3% | 12.7% |
| 1 Year | 46.4%46.4% | 46.0%45.7% | 22.3%19.5% |
| 3 Year | -6.2%-6.2% | 109.2%107.9% | 44.4%34.8% |
| 5 Year | -6.8%-6.8% | 229.6%225.5% | 128.7%103.3% |
Long-Term Price Volatility Vs. Market
How volatile is Fluidigm's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 days ago | Simply Wall St
Have Insiders Been Buying Fluidigm Corporation (NASDAQ:FLDM) Shares?1 month ago | Simply Wall St
The Fluidigm (NASDAQ:FLDM) Share Price Is Up 110% And Shareholders Are Boasting About It2 months ago | Simply Wall St
News Flash: Analysts Just Made A Notable Upgrade To Their Fluidigm Corporation (NASDAQ:FLDM) ForecastsValuation
Is Fluidigm undervalued compared to its fair value and its price relative to the market?
3.01x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate FLDM's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate FLDM's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: FLDM is unprofitable, so we can't compare its PE Ratio to the US Life Sciences industry average.
PE vs Market: FLDM is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate FLDM's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: FLDM is good value based on its PB Ratio (3x) compared to the US Life Sciences industry average (8.4x).
Next Steps
Future Growth
How is Fluidigm forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
14.5%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: FLDM is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: FLDM is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: FLDM is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: FLDM's revenue (12.8% per year) is forecast to grow faster than the US market (10.3% per year).
High Growth Revenue: FLDM's revenue (12.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: FLDM's Return on Equity is forecast to be low in 3 years time (9.3%).
Next Steps
Past Performance
How has Fluidigm performed over the past 5 years?
1.3%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: FLDM is currently unprofitable.
Growing Profit Margin: FLDM is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: FLDM is unprofitable, but has reduced losses over the past 5 years at a rate of 1.3% per year.
Accelerating Growth: Unable to compare FLDM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: FLDM is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (30.4%).
Return on Equity
High ROE: FLDM has a negative Return on Equity (-31.37%), as it is currently unprofitable.
Next Steps
Financial Health
How is Fluidigm's financial position?
Financial Position Analysis
Short Term Liabilities: FLDM's short term assets ($122.7M) exceed its short term liabilities ($42.8M).
Long Term Liabilities: FLDM's short term assets ($122.7M) do not cover its long term liabilities ($128.2M).
Debt to Equity History and Analysis
Debt Level: FLDM's debt to equity ratio (35.6%) is considered satisfactory.
Reducing Debt: FLDM's debt to equity ratio has reduced from 157.8% to 35.6% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: FLDM has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: FLDM has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 6.2% each year
Next Steps
Dividend
What is Fluidigm current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate FLDM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate FLDM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if FLDM's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if FLDM's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of FLDM's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
4.3yrs
Average management tenure
CEO
Chris Linthwaite (47 yo)
4.25yrs
Tenure
US$3,713,055
Compensation
Mr. Stephen Christopher Linthwaite, also known as Chris, has been the President of Fluidigm Corporation since August 4, 2016. Mr. Linthwaite has been the Chief Executive Officer of Fluidigm Corporation si...
CEO Compensation Analysis
Compensation vs Market: Chris's total compensation ($USD3.71M) is above average for companies of similar size in the US market ($USD1.67M).
Compensation vs Earnings: Chris's compensation has increased whilst the company is unprofitable.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 4.25yrs | US$3.71m | 0.20% $ 898.2k | |
| Chief Financial Officer | 12.92yrs | US$1.39m | 0.16% $ 728.4k | |
| Senior Vice President of Global Operations | 2.75yrs | US$1.35m | 0.040% $ 184.9k | |
| Senior VP | 4.58yrs | US$1.26m | 0.068% $ 313.1k | |
| Chief Commercial Officer | 1.83yrs | US$1.96m | 0.027% $ 124.1k | |
| Co-Founder & Chairman of Advisory Board | no data | no data | no data | |
| Chief Science Officer | 1.58yrs | no data | no data | |
| Vice President of Investor Relations | no data | no data | no data | |
| Senior Director of Corporate Communications | no data | no data | no data | |
| Chief Human Resources Officer | 3.5yrs | no data | no data | |
| MD of Fluidigm Singapore Pte Ltd & EVP of Worldwide Manufacturing - Fluidigm Singapore Pte Ltd | 14.83yrs | US$748.30k | no data | |
| Director of Corporate & Strategic Finance | no data | no data | no data |
4.3yrs
Average Tenure
47yo
Average Age
Experienced Management: FLDM's management team is considered experienced (4.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 4.25yrs | US$3.71m | 0.20% $ 898.2k | |
| Co-Founder & Chairman of Advisory Board | no data | no data | no data | |
| Independent Director | 20.5yrs | US$200.46k | 0.30% $ 1.4m | |
| Independent Director | 8yrs | US$164.47k | 0.011% $ 49.4k | |
| Member of Advisory Board | 14.08yrs | no data | no data | |
| Member of Advisory Board | 20.08yrs | no data | no data | |
| Member of Advisory Board | 21.08yrs | no data | no data | |
| Member of Advisory Board | 18.58yrs | no data | no data | |
| Independent Director | 2.25yrs | US$153.47k | 0% $ 0 | |
| Independent Chairman of the Board | 0.58yr | US$153.96k | 0.058% $ 267.9k | |
| Independent Director | 1.5yrs | US$131.31k | no data | |
| Independent Director | 3.83yrs | US$163.22k | 0.19% $ 867.8k |
8.0yrs
Average Tenure
59.5yo
Average Age
Experienced Board: FLDM's board of directors are considered experienced (8 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 6.5%.
Top Shareholders
Company Information
Fluidigm Corporation's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Fluidigm Corporation
- Ticker: FLDM
- Exchange: NasdaqGS
- Founded: 1999
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$458.055m
- Shares outstanding: 74.12m
- Website: https://www.fluidigm.com
Number of Employees
Location
- Fluidigm Corporation
- 2 Tower Place
- Suite 2000
- South San Francisco
- California
- 94080
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| FLDM | NasdaqGS (Nasdaq Global Select) | Yes | Common Stock | US | USD | Feb 2011 |
| FLB | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Feb 2011 |
Biography
Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research worldwide. It offers analytical systems comprising Helios, a CyTOF system, Hyperion imaging system,...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/01/18 23:52 |
| End of Day Share Price | 2021/01/15 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.